| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

2 November 2020

Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director and retirement of Dr. Tamara Maes

26 October 2020

ORYZON Reports Results for Quarter Ended September 30, 2020 and Provides Corporate Update

20 October 2020

ORYZON holds its 4th annual Solidarity Day

15 October 2020

ORYZON publishes paper in Journal of Clinical Oncology demonstrating relevance of iadademstat in leukemia

17 September 2020

ORYZON presents efficacy and safety results of its CLEPSIDRA trial with iadademstat in ED-SCLC patients at ESMO-2020

21-24 September 2020

Sachs 20th Annual Biotech in Europe Forum

16-21 September 2020

ESMO Virtual Congress 2020

14-16 September 2020

H.C. Wainwright 22nd Annual Global Investment Conference

8 September 2020

ORYZON to present at upcoming international conferences

2 September 2020

Annual General Shareholders Meeting 2020

Pagination

First page «
Previous page ‹
Page 26
Page 27
Page 28
Page 29
Current page 30
Page 31
Page 32
Page 33
Page 34
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel